Boston Family Office LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)

Boston Family Office LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,219 shares of the company’s stock after selling 1,742 shares during the quarter. Boston Family Office LLC’s holdings in Johnson & Johnson were worth $14,133,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of JNJ. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $49,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $50,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.2%

Shares of Johnson & Johnson stock opened at $176.76 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a fifty day moving average price of $161.28 and a 200 day moving average price of $158.34. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $177.27. The stock has a market cap of $425.70 billion, a PE ratio of 18.90, a price-to-earnings-growth ratio of 2.23 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter last year, the company posted $2.82 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson’s payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on JNJ. Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. UBS Group lifted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Finally, Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.